Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

NCT01160861 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01160861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01160861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 11, 2010
Completion date
April 30, 2011
Enrollment
36 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis